Bristol Will Use Yervoy’s Successful Launch As Model For Opdivo
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma posted strong results in the third quarter for its oncology franchise, but looks to its future in cancer immunotherapy to bring about growth post-patent losses.
You may also be interested in...
Emerging Markets Earnings: BMS Eyes HCV In Japan, China HIV Sales Slow
Bristol-Myers Squibb provides few insights into emerging markets earnings, though it fills in some color on HCV in Japan and China HIV sales.
Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.